The FDA has approved adalimumab (Humira, Abbott) to treat adults with moderately to severely active Crohn’s disease, a chronic inflammatory disease of the intestines. This monoclonal antibody helps to reduce excessive levels of human tumor necrosis factor-alpha, which plays a role in abnormal inflammatory and immune responses.
The labeling includes a boxed warning about potential serious adverse events, including tuberculosis, opportunistic infections, and sepsis. canadian pharmacy online
Adalimumab was previously approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spon-dylitis.
For more information on adalimumab, see Meeting Highlights.